KR101841756B1 - 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용 - Google Patents

지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용 Download PDF

Info

Publication number
KR101841756B1
KR101841756B1 KR1020117023450A KR20117023450A KR101841756B1 KR 101841756 B1 KR101841756 B1 KR 101841756B1 KR 1020117023450 A KR1020117023450 A KR 1020117023450A KR 20117023450 A KR20117023450 A KR 20117023450A KR 101841756 B1 KR101841756 B1 KR 101841756B1
Authority
KR
South Korea
Prior art keywords
delete delete
fatty acid
oil mixture
dha
epa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117023450A
Other languages
English (en)
Korean (ko)
Other versions
KR20110126746A (ko
Inventor
스베인 올라프 허스트베드트
프레벤 호울버그 올레센
군나르 버게
조 에릭 존스러드 클라베네쓰
Original Assignee
프로노바 바이오파마 너지 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로노바 바이오파마 너지 에이에스 filed Critical 프로노바 바이오파마 너지 에이에스
Publication of KR20110126746A publication Critical patent/KR20110126746A/ko
Application granted granted Critical
Publication of KR101841756B1 publication Critical patent/KR101841756B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020117023450A 2009-03-09 2010-03-09 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용 Active KR101841756B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15861309P 2009-03-09 2009-03-09
US61/158,613 2009-03-09
US24263009P 2009-09-15 2009-09-15
US61/242,630 2009-09-15
US25429109P 2009-10-23 2009-10-23
US25429309P 2009-10-23 2009-10-23
US61/254,293 2009-10-23
US61/254,291 2009-10-23
PCT/IB2010/000824 WO2010103404A1 (en) 2009-03-09 2010-03-09 Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187007824A Division KR101966874B1 (ko) 2009-03-09 2010-03-09 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도

Publications (2)

Publication Number Publication Date
KR20110126746A KR20110126746A (ko) 2011-11-23
KR101841756B1 true KR101841756B1 (ko) 2018-03-23

Family

ID=42727856

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197009512A Active KR102118478B1 (ko) 2009-03-09 2010-03-09 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도
KR1020117023450A Active KR101841756B1 (ko) 2009-03-09 2010-03-09 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용
KR1020187007824A Active KR101966874B1 (ko) 2009-03-09 2010-03-09 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197009512A Active KR102118478B1 (ko) 2009-03-09 2010-03-09 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187007824A Active KR101966874B1 (ko) 2009-03-09 2010-03-09 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도

Country Status (17)

Country Link
US (6) US11612579B2 (enExample)
EP (4) EP2405903B1 (enExample)
JP (4) JP6176894B2 (enExample)
KR (3) KR102118478B1 (enExample)
CN (3) CN104146955A (enExample)
AU (1) AU2010222648B2 (enExample)
BR (1) BRPI1009431A2 (enExample)
CA (2) CA3065860A1 (enExample)
CO (1) CO6501136A2 (enExample)
EA (1) EA022028B1 (enExample)
ES (3) ES2894340T3 (enExample)
IL (1) IL215043A (enExample)
MX (1) MX2011009503A (enExample)
NZ (1) NZ595204A (enExample)
PH (1) PH12019500030A1 (enExample)
SG (1) SG174314A1 (enExample)
WO (3) WO2010119319A1 (enExample)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119319A1 (en) * 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SI2443246T1 (en) 2009-06-15 2018-05-31 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
ES2661812T3 (es) * 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
WO2011048493A1 (en) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
AR078850A1 (es) 2009-10-29 2011-12-07 Acasti Pharma Inc Composiciones terapeuticas concentradas de fosfolipidos
ES2862980T3 (es) 2009-12-30 2021-10-08 Basf Pharma Callanish Ltd Composiciones de ácido graso poliinsaturado obtenibles mediante un proceso de separación cromatográfica en lecho móvil simulado
AU2010343305B2 (en) 2010-01-19 2015-06-11 Dsm Ip Assets B.V. Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
US11236351B2 (en) 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
JP2013537185A (ja) * 2010-09-08 2013-09-30 プロノヴァ・バイオファーマ・ノルゲ・アーエス 遊離酸の形のｅｐａおよびｄｈａを含む脂肪酸油混合物と界面活性剤とスタチンとを含む組成物
US20140017308A1 (en) * 2010-09-08 2014-01-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
JP2014505017A (ja) * 2010-11-05 2014-02-27 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物を用いる処置方法
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CA2827561A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
EP2675442A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
CA2827579A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US8951514B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
EP2675445A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
US8697676B2 (en) 2011-06-15 2014-04-15 Ronald E Rosedale Omega-3 fatty acid nutriceutical composition and optimization method
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
US20140323569A1 (en) * 2011-07-21 2014-10-30 Krishna Raman Microbial oils enriched in polyunsaturated fatty acids
TWI582235B (zh) 2011-07-21 2017-05-11 Ｄｓｍ智慧財產有限公司 生產二十碳五烯酸之微生物、脂肪酸組成物及其製作方法與用途
TW201307553A (zh) * 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013072767A1 (en) * 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
SG10201701004RA (en) 2012-01-06 2017-04-27 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US20150132389A1 (en) * 2012-03-30 2015-05-14 Sancilio & Company, Inc. Omega-3 Fatty Acid Ester Compositions
MY189576A (en) 2012-03-30 2022-02-17 Micelle Biopharma Inc Omega-3 fatty acid ester compositions
US9480651B2 (en) * 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US10898458B2 (en) * 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20150125529A1 (en) * 2012-03-30 2015-05-07 Sancilio & Company, Inc. Omega-3 Fatty Acid Ester Compositions
HK1206248A1 (en) 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
KR20220140655A (ko) 2012-05-14 2022-10-18 닛폰 스이산 가부시키가이샤 환경 오염 물질을 저감시킨 고도 불포화 지방산 또는 고도 불포화 지방산 에틸에스테르 및 그 제조 방법
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20140194512A1 (en) * 2012-06-17 2014-07-10 Matinas Biopharma, Inc. Compositions comprising docosapentaenoic acid and methods of use
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
CN103015230B (zh) * 2012-11-27 2015-04-01 广州嘉德乐生化科技有限公司 一种单硬脂酸甘油酯和聚氧乙烯醚脂肪酸皂的组合物
CA2894183A1 (en) * 2012-12-06 2014-06-12 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US11351139B2 (en) * 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
JP2016518315A (ja) * 2013-03-13 2016-06-23 マティナス バイオファーマ インコーポレイテッド ω３ペンタエン酸組成物および使用方法
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
WO2014179325A1 (en) * 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
CN111888343A (zh) * 2013-07-18 2020-11-06 持田制药株式会社 ω-3脂肪酸的自乳化组合物
CA2918336C (en) * 2013-07-18 2022-05-24 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
WO2015011724A2 (en) * 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3118186B1 (fr) 2013-12-11 2022-02-09 Novasep Process Installation chromatographique de production d acides gras polyinsatures
EP4223861A3 (en) 2013-12-20 2023-11-01 Mara Renewables Corporation Methods of recovering oil from microorganisms
BR112016015718B1 (pt) 2014-01-07 2021-12-07 Novasep Process Solutions Processo de purificação de aminoácidos aromáticos
CA2937167C (en) * 2014-01-28 2022-06-21 Fresenius Kabi Deutschland Gmbh Composition comprising epa and dha triglycerides for parenteral administration
WO2015155703A2 (en) 2014-04-09 2015-10-15 Nanoceutica Laboratories Pvt. Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016071434A1 (en) * 2014-11-05 2016-05-12 Abbott Laboratories Gmbh Processes for producing compositions with improved safety profile comprising pancreatin and compositions suitable for pharmaceutical use
CN105614638A (zh) * 2014-11-28 2016-06-01 深圳市前海安测信息技术有限公司 Dha纳米乳及其制备方法和其在健康保健饮品中的应用
US11007161B1 (en) * 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10561627B2 (en) * 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
RU2709612C2 (ru) 2015-01-21 2019-12-19 Мотида Фармасьютикал Ко., Лтд. САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
WO2016195016A1 (ja) * 2015-06-02 2016-12-08 日東薬品工業株式会社 新規なトリグリセリド及びその用途
RU2655803C2 (ru) * 2016-03-10 2018-05-29 АД Смарт, СИА Фармацевтическая композиция для профилактики и лечения атеросклероза
ES2836729T3 (es) * 2016-03-16 2021-06-28 Golden Omega Norway As Polvos y comprimidos que contienen derivados de ácidos grasos omega-3 y procedimiento para su producción
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
CN106072611A (zh) * 2016-06-20 2016-11-09 威海百合生物技术股份有限公司 一种含不饱和脂肪酸的多相稀释组合物
GB201611920D0 (en) * 2016-07-08 2016-08-24 Astrazeneca Ab Pharmaceutical compositions
US11241408B2 (en) * 2016-08-12 2022-02-08 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
WO2018054265A1 (zh) * 2016-09-20 2018-03-29 张碧婷 亲水性脂类组合物的包装组合物，其制备及调配方法和应用
CN110168071A (zh) 2016-12-22 2019-08-23 玛拉可再生能源公司 用于使用真核微生物产生富含dha、棕榈酸和蛋白质的生物质的方法
CN107048405A (zh) * 2017-03-03 2017-08-18 武汉锶博睿医药技术有限公司 脂肪酸组件微胶囊及其制备方法
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
HUE067138T2 (hu) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban
PL3886908T3 (pl) 2018-11-30 2025-09-29 Evonik Operations Gmbh Preparat zawierający dyspersję fosfolipidów i soli kwasów tłuszczowych
JP2022529982A (ja) 2019-04-18 2022-06-27 アーケシュフース ウニヴェルスィテーツスィーケフース ハーエフ ＦＦＡＲ４アゴニストと、α７ ｎＡＣｈＲアゴニスト又はポジティブモジュレーターとを含む併用療法
KR102096391B1 (ko) * 2019-10-11 2020-04-06 (주)아이엠디팜 액상결정 구조체를 형성하는 오메가-3-지방산 조성물
CN110584084A (zh) * 2019-10-17 2019-12-20 广州白云山汉方现代药业有限公司 一种乳化稳定剂及含该乳化稳定剂的营养乳液
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
WO2021199009A1 (en) 2020-04-03 2021-10-07 MARA Renewables Corporation Microbial oils with high levels of omega-3 fatty acids
CN113827547A (zh) * 2020-06-23 2021-12-24 南京清普生物科技有限公司 一种缓释制剂组合物
CN111729125B (zh) * 2020-07-31 2022-10-04 陕西佰傲再生医学有限公司 骨止血材料
JP2021008518A (ja) * 2020-10-21 2021-01-28 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN116407543B (zh) * 2021-12-29 2025-12-12 中国科学院上海药物研究所 Epa-ee纳米脂质组合物、及其制剂、制备方法和应用
KR20230161551A (ko) * 2022-05-18 2023-11-28 부광약품 주식회사 제제학적으로 안정성이 향상된 연질 캡슐

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (enExample) 1971-05-24 1978-05-01
GB2033745B (en) 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
AU552068B2 (en) 1981-09-21 1986-05-22 Asama Chemical Co. Ltd. Preservation of edible oils
WO1984002271A1 (en) 1982-12-09 1984-06-21 Hafsten Raymond J Jr Readily-absorpable fatty acid emulsions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5532002A (en) * 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
DE69013923T2 (de) 1989-08-17 1995-03-16 Cortecs Ltd., Isleworth Arzneiformulierungen.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5501077A (en) * 1994-05-27 1996-03-26 Springwell Dispensers, Inc. Thermoelectric water chiller
JPH0889167A (ja) 1994-09-27 1996-04-09 Nippon Oil & Fats Co Ltd 多価不飽和脂肪酸含有醗酵乳の製造方法
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
KR100300251B1 (ko) 1997-12-05 2001-10-29 김용규 사이클로스포린함유약학적조성물
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
AU1809499A (en) 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
EP1075252A2 (en) * 1998-05-07 2001-02-14 ELAN CORPORATION, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20050037065A1 (en) 1999-05-27 2005-02-17 Drugtech Corporation Nutritional formulations
ES2246769T3 (es) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
GB0210212D0 (en) 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
ITMI20022511A1 (it) 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
WO2004056370A1 (en) 2002-12-20 2004-07-08 Pronova Biocare As Use of a fatty acid composition for treatment of male infertility
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
KR20070038553A (ko) * 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
US20090030077A1 (en) * 2004-08-06 2009-01-29 Transform Pharmaceuticals Inc. Novel Fenofibrate Formulations and Related Methods of Treatment
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
ZA200702216B (en) * 2004-08-18 2008-11-26 Ace Aps Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
EP1845999A4 (en) * 2005-01-24 2010-09-22 Pronova Biocare As USE OF A DHA-CONTAINING FATTY ACID COMPOSITION FOR THE PRODUCTION OF A PHARMACEUTICAL OR FOOD PRODUCT FOR THE TREATMENT OF AMYLOSIS RELATED DISEASES
KR20070108945A (ko) 2005-03-08 2007-11-13 릴라이언트 파마슈티컬스 인코퍼레이티드 스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료
BRPI0613704A2 (pt) 2005-07-08 2011-02-01 Mochida Pharm Co Ltd composição para impedir o inìcio e/ou a recorrência de eventos cardiovasculares
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
WO2007075841A1 (en) 2005-12-20 2007-07-05 Cenestra, Llc Omega 3 fatty acid formulations
AU2007214127A1 (en) 2006-02-10 2007-08-16 Sportscom Danmark Aps Coated tablets, their methods of preparation, and related uses
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
WO2008011179A2 (en) * 2006-07-21 2008-01-24 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids for use in treating resistant hypertension
US7676518B2 (en) 2006-08-16 2010-03-09 Sap Ag Clustering for structured data
JP2010506920A (ja) 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
AU2008229604B2 (en) * 2007-03-20 2013-05-30 Scf Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
WO2008116806A1 (en) 2007-03-23 2008-10-02 Novartis Ag Use of a masked or coated copper salt for the treatment of macular degeneration
US20080261896A1 (en) * 2007-04-11 2008-10-23 Sinphar Pharmaceutical Co., Ltd. Testosterone generating and metabolizing enhancer
WO2009009040A2 (en) 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
US8370627B2 (en) 2008-01-04 2013-02-05 University Of Yamanashi Confidential communication method
CA2711814A1 (en) 2008-01-10 2009-07-16 Takeda Pharmaceutical Company Limited Capsule formulation
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
WO2010040012A1 (en) 2008-10-01 2010-04-08 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2010119319A1 (en) * 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
ES2661812T3 (es) 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
WO2011048493A1 (en) 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture

Also Published As

Publication number Publication date
AU2010222648B2 (en) 2016-07-07
ES2979118T3 (es) 2024-09-24
EP2405895A1 (en) 2012-01-18
JP6723009B2 (ja) 2020-07-15
US20210085632A1 (en) 2021-03-25
CO6501136A2 (es) 2012-08-15
BRPI1009431A2 (pt) 2016-03-01
NZ595204A (en) 2014-11-28
PH12019500030A1 (en) 2020-02-10
EP2405895B1 (en) 2021-05-12
EP2405902B1 (en) 2021-07-21
US11395811B2 (en) 2022-07-26
CN104146955A (zh) 2014-11-19
KR20180032670A (ko) 2018-03-30
EP2405903A4 (en) 2012-10-10
EP3915554A1 (en) 2021-12-01
US20120225945A1 (en) 2012-09-06
WO2010103402A1 (en) 2010-09-16
WO2010119319A1 (en) 2010-10-21
EP2405903A1 (en) 2012-01-18
KR20190039342A (ko) 2019-04-10
US20190183838A1 (en) 2019-06-20
JP2016128425A (ja) 2016-07-14
US20120196934A1 (en) 2012-08-02
JP2018090600A (ja) 2018-06-14
CN110538148A (zh) 2019-12-06
US9532963B2 (en) 2017-01-03
IL215043A0 (en) 2011-11-30
CA3065860A1 (en) 2010-09-16
EP2405902A4 (en) 2012-10-10
JP2012519728A (ja) 2012-08-30
ES2894340T3 (es) 2022-02-14
US20170112795A1 (en) 2017-04-27
KR101966874B1 (ko) 2019-04-08
CA2754860C (en) 2020-02-25
ES2881885T3 (es) 2021-11-30
WO2010103404A1 (en) 2010-09-16
SG174314A1 (en) 2011-10-28
CA2754860A1 (en) 2010-09-16
EP2405903B1 (en) 2024-04-10
US11612579B2 (en) 2023-03-28
AU2010222648A1 (en) 2011-10-06
US10596142B2 (en) 2020-03-24
EA022028B1 (ru) 2015-10-30
JP7199389B2 (ja) 2023-01-05
EA201171113A1 (ru) 2012-07-30
JP2020079286A (ja) 2020-05-28
KR102118478B1 (ko) 2020-06-04
EP2405902A1 (en) 2012-01-18
US11523999B2 (en) 2022-12-13
KR20110126746A (ko) 2011-11-23
US10028928B2 (en) 2018-07-24
MX2011009503A (es) 2011-09-28
IL215043A (en) 2016-11-30
EP2405895A4 (en) 2012-10-10
US20120232141A1 (en) 2012-09-13
JP6176894B2 (ja) 2017-08-09
CN102421422A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
KR101841756B1 (ko) 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용
KR101904388B1 (ko) 지방산 오일 혼합물의 코팅된 캡슐 및 정제
US20230218560A1 (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111005

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150128

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160629

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161020

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160629

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161020

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160829

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150128

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161209

Patent event code: PE09021S01D

AMND Amendment
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170531

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20171219

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170831

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170309

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20161123

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20161020

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160829

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150128

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180319

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180319

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180320

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210303

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220304

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240304

Start annual number: 7

End annual number: 7